

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup>:</b> <b>A61K 38/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/12111</b> <b>(43) International Publication Date:</b> 9 March 2000 (09.03.00)
<b>(21) International Application Number:</b> PCT/CA99/00800 <b>(22) International Filing Date:</b> 1 September 1999 (01.09.99)  <b>(30) Priority Data:</b> 2,246,791 1 September 1998 (01.09.98) CA  <b>(71) Applicants (for all designated States except US):</b> THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; The Industry Liaison Office, Office of Research Services and Industry, I.R.C. Room 331, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA). QLT PHOTO THERAPEUTICS INC. [CA/CA]; 520 West 6th Avenue, Vancouver, British Columbia V5Z 4H5 (CA).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HSIANG, York [CA/CA]; 3376 West 34th Avenue, Vancouver, British Columbia V6N 2K6 (CA). BUCHAN, Alison [CA/CA]; Department of Physiology, 2146 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA). LEVY, Julia, G. [CA/CA]; #601 - 1490 Pennyfarthing Drive, Vancouver, British Columbia V6G 4Z3 (CA). MARGARON, Philippe, Maria, Clotaire [CA/CA]; #35 - 7128 - 18th Avenue, Burnaby, British Columbia V3N 1H1 (CA).		<b>(74) Agents:</b> KINGWELL, Brian, G. et al.; Smart & Biggar, Vancouver Centre, Suite 2200, Box 11560, 650 West Georgia Street, Vancouver, British Columbia V6B 4N8 (CA).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> SELECTIVE TREATMENT OF ENDOTHELIAL SOMATOSTATIN RECEPTORS		
<b>(57) Abstract</b>		
<p>The invention provides for the use of a SSTR1 or SSTR4 selective agonist to treat human endothelial cells and to formulate a medicament for human use, where the medicament may be for use to treat an endothelial-cell-mediated proliferative disease. The use of SSTR1 or SSTR4 selective agonists for treating endothelial-cell-mediated proliferative diseases may include, for example, treatment of intimal hyperplasia or an angiogenic disease. In various embodiments, the angiogenic disease may for example be macular degeneration, or a solid tumor. The SSTR1 or SSTR4 selective agonists may include the SSTR1 <sup>4</sup>99 agonist (des-AA<sup>1,2,5</sup>[DTp<sup>8</sup>,IAamp<sup>9</sup>]SS). In methods of treatment, therapeutically effective amounts of the SSTR1 or SSTR4 selective agonists may be administered to a patient.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## SELECTIVE TREATMENT OF ENDOTHELIAL SOMATOSTATIN RECEPTORS

### FIELD OF THE INVENTION

5           The invention is in the field of therapeutic uses for selective peptide and nonpeptide somatostatin receptor agonists.

### BACKGROUND OF THE INVENTION

10           Somatostatin (SS) is an endogenous cyclic peptide found in two major native molecular forms of 28 and 14 amino acids (SS28 and SS14 respectively, SS was initially described as a somadomedin release-inhibiting factor, and is consequently still called SRIF in some of the literature). SS has disparate, but primarily inhibitory, roles in a variety of physiological systems, either acting directly on cellular functions or as an antagonist of stimulatory factors (Coy *et al.* 1993, *J. Pediatric Endocrinol.*  
15 6:205). The multiplicity of effects of SS on physiological processes reflects both its widespread distribution *in vivo*, and the existence of multiple SS receptor subtypes.

          The effects of SS are transduced by a family of SS receptors (SSTRs), of which 5 (SSTR1 through SSTR5) have been cloned (Coy *et al.* 1993, *supra*). These  
20 receptors may be divided into two sub-groups on the basis of their relative sequence similarities and affinity for SS analogues (Hoyer *et al.*, 1995, *Trends Pharmacol Sci* 16:86). One sub-group consists of SSTR2, SSTR3 and SSTR5. The second sub-group comprising SSTR1 and SSTR4. The physiology of the first sub-group of receptors has been more thoroughly characterized, due in part to the relative availability of SS  
25 analogues that are selective for these SSTRs, particularly SSTR2. It is however known that all 5 SSTRs share some mechanistic features, for example all 5 have been shown to be coupled to G-proteins and to regulate intracellular cAMP levels, in part, through activation of G<sub>i</sub> (Patel *et al.* 1994, *Biochem. Biophys Res. Commun.* 198:605).

30           SS has an extremely short half life *in vivo*, rendering it unsuitable for most therapeutic uses. For therapeutic applications, a variety of short peptide analogues of SS have been identified, particularly agonists of the first sub-group of SSTRs (see for example U.S. Patent Nos. 4,485,101 issued 27 November 1984; 4,904,642 issued 27

February 1990; 5,147,859 issued 15 September 1992; 5,409,894 issued 25 April 1995; 5,597,894 issued 28 January 1997; and, International Patent Publications: WO 97/01579 of 16 January 1997 and WO 97/47317 of 18 December 1997; all of which are hereby incorporated by reference).

5

Among the most thoroughly characterized of the peptide SSTR agonists are octreotide (Sandoz Ltd., Basel, Switzerland) and angiopeptin (sometimes referred to as BIM 23014). Octreotide is recognized as an SSTR2 selective agonist (Yang *et al.*, 1998, *PNAS USA* 95:10836). Angiopeptin is recognized as an SSTR2/SSTR5 selective agonist (Alderton *et al.*, 1998, *Br. J. Pharmacol* 124(2):323). U.S. Patent No. 5,750,499 (issued 12 May 1998 to Hoeger *et al.*, incorporated herein by reference) discloses what are claimed therein to be the first SSTR1 selective agonists (also described in Liapakis *et al.*, 1996, *The J. of Pharmacology and Experimental Therapeutics* 276(3):1089, incorporated herein by reference), one of which is identified as des-AA<sup>1,2,5</sup> [DTrp<sup>8</sup>, LAamp<sup>9</sup>]SS (*i.e.* des-amino acid<sup>1,2,5</sup> [DTryptophan<sup>8</sup>, N-p-isopropyl-4-aminomethyl-L-phenylalanine<sup>9</sup>]SS, abbreviated herein as the "SSTR1 '499 agonist").

A number of nonpeptide somatostatin receptor subtype-selective agonists have been identified using combinatorial chemistry (Rohrer *et al.* 1998, *Science* 282:737, incorporated herein by reference). Included amongst the agonists identified by Rhorer *et al., supra*, are agonists selective for SSTR1 and SSTR4. Rhorer *et al., supra*, also disclose the apparent inhibition constant ( $K_i$ ) for SS14 binding to the SSTR receptors, as shown in Table 1, and disclose methods of calculating that constant for SSTR selective agonists. Rhorer *et al., supra*, indicate that the SSTR1 and SSTR4 agonists disclosed therein were not physiologically active, in that they did not inhibit the release of growth hormone, glucagon or insulin in a model system. In contrast, a SSTR2 agonist is disclosed as having potent inhibitory effects on secretion of growth hormone, glucagon and insulin.

30

Table 1: SS14 SSTR Specificity ( $K_i$  in nanomoles)\*:

	SSTR1	SSTR2	SSTR3	SSTR4	SSTR5
SS14	0.4	0.04	0.7	1.7	2.3

\* From Rohrer *et al.* 1998, *Science* 282:737.

It has been suggested that particular SSTR agonists may be useful in the treatment of a variety of diseases, particularly in light of favourable results of treatment in some animal models. For example, on the basis of the chicken chorioallantoic membrane (CAM) model, it has been suggested that SSTR2 agonists in particular may be effective inhibitors of angiogenesis (Woltering *et al.* 1997, *Investigational New Drugs* 15:77, in which SSTR2 binding activity of a number of agonists is correlated with the compounds anti-angiogenic activity). With respect to angiogenesis, SS itself has recently been shown to control growth of a xenografted Kaposi's sarcoma tumor in a nude mouse model, through inhibition of murine angiogenesis (Albini *et al.* 1999, *The FASEB J.* 13(6):647, wherein results are presented indicating that human endothelial cells express SSTR3). There is also abundant evidence that SSTR2 agonists, particularly angiopeptin, are effective in inhibiting intimal hyperplasia after arterial injury in animal models (Lundergan *et al.* 1989, *Atherosclerosis* 80:49; Foegh *et al.*, 1989, *Atherosclerosis* 78:229; Conte *et al.*, 1989, *Transpl Proc* 21:3686; Vargas *et al.*, 1989, *Transplant Proc* 21:3702; Hong *et al.*, 1993, *Circulation* 88:229; Leszczynski *et al.*, 1993, *Regulatory peptides* 43:131; Mooradian *et al.*, 1995, *J. Cardiovasc Pharm* 25:611; Light *et al.*, 1993, *Am J Physiol* 265:H1265). It has been suggested that this therapeutic activity in animal models reflects the ability of angiopeptin to inhibit the release of growth factors from injured endothelial cells (Hayry *et al.*, 1996, *Metabolism* 45(8 Suppl 1):101). In clinical studies, however, the use of angiopeptin to inhibit intimal hyperplasia causing restenosis in human patients has been inconclusive (Eriksen *et al.*, 1995, *Am Heart J.* 130:1; Emanuelsson *et al.*, 1995, *Circulation* 91:1689; Kent *et al.*, 1993, *Circulation* 88:I506). The poor clinical efficacy of angiopeptin in clinical trials for the prophylaxis of restenosis following coronary angioplasty, in contrast to encouraging data from animal studies, has been attributed to a low intrinsic activity of angiopeptin at the SSTR2 receptor, combined with lack of agonist activity at the SSTR5 receptor (Alderton *et al.* 1998, *Br. J. Pharmacol* 124(2):323). SSTR2 agonists have also been

found to be generally ineffective in the treatment of diabetic retinopathy (Kirkegaard *et al.*, 1990, *Acta Endocrinologica (Copenh)* 122:766), despite the indications from *in vitro* and animal studies that such compounds exhibit anti-angiogenic activity.

5           Endothelial cells form a single cell layer lining all blood vessels in the human body, surrounded by other cell types such fibroblasts and smooth muscle cells. Endothelial cells are restricted to blood vessels. Endothelial-cell-mediated proliferative diseases such as angiogenic diseases and intimal hyperplasia continue to pose a significant health problem, caused by imbalances in the physiological system  
10   that regulates vascular remodelling. For example, ocular neovascularization in diseases such as age-related macular degeneration and diabetic retinopathy constitute one of the most common causes of blindness. Intimal hyperplasia causing restenosis or narrowing of the artery has been found to occur in 30-50% of coronary angioplasties and following approximately 20% of bypass procedures (McBride *et al.*,  
15   1988, *N. Engl. J. Med.* 318:1734; Clowes, 1986, *J. Vasc. Surg.* 3:381). Angiogenesis induced by solid tumor growth may lead not only to enlargement of the primary tumor, but also to metastasis via the new vessels.

#### SUMMARY OF THE INVENTION

20           The inventors have made the surprising discovery that SSTR1 and SSTR4 are expressed on human endothelial cells, *in vitro* and *in vivo*, which contrasts with the presence of other SSTRs, particularly SSTR2, on endothelial cells in other animals. Accordingly, SSTR1 and SSTR4 selective agonists may be used to treat human endothelial-cell-mediated proliferative diseases. In some aspects of the invention, the  
25   use of selective agonists targeted to endothelial cells may have the important advantage of minimizing the side effects that would otherwise be associated with stimulating the SSTRs that are present on other cells, particularly SSTR2 on endocrine cells. The invention therefore provides for the use of a SSTR1 or SSTR4 selective agonist to formulate a medicament for human use, where the medicament  
30   may be for use to treat an endothelial-cell-mediated proliferative disease. The use of SSTR1 or SSTR4 selective agonists for treating endothelial-cell-mediated proliferative diseases may include, for example, treatment of intimal hyperplasia or an angiogenic disease. In various embodiments, the angiogenic disease may for

example be age-related macular degeneration, or a solid tumour. The SSTR1 selective agonists may be the SSTR1 '499 agonist (des-AA<sup>1,2,5</sup> [DTrp<sup>8</sup>, LAamp<sup>9</sup>]SS). In methods of treatment, therapeutically effective amounts of the SSTR1 or SSTR4 selective agonists may be administered to a patient.

5

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph showing the anti-angiogenic effects of SS14 in the ECV304/Matrigel model (Hughes, 1996, *Experimental Cell Research* 225:171-185), as disclosed in Example 1 herein.

10

## DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the invention provides therapeutic uses of SSTR1 and SSTR4 selective agonists. In some embodiments, the invention involves the use of SSTR1 and SSTR4 selective agonists for the treatment of endothelial-cell-mediated proliferative diseases. Examples of endothelial-cell-mediated proliferative diseases include intimal hyperplasia and angiogenic diseases (angiogenic diseases are characterised by pathological neovascularization as a result of inappropriate or unregulated angiogenesis). Proliferative diseases may be mediated by endothelial cells, for example, where endothelial cells are involved in up-regulating a pathological cellular proliferation, as is thought to occur in intimal hyperplasia (where the proliferating cells may be either endothelial or other cell types), or, as in the case of solid tumour vascularization, where the endothelial cells facilitate pathological cellular proliferation. The categories of endothelial-cell-mediated proliferative diseases will be recognisable by medical practitioners and those skilled in this art, and will change from time-to-time in accordance with progress in medical research.

25

In various aspects of the invention, angiogenic diseases may include proliferative retinopathies, such as diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, retrolental fibroplasia, neovascular glaucoma, rubeosis, retinal neovascularization due to macular degeneration (including anti-angiogenic treatment following photodynamic therapy), hypoxia, angiogenesis in the eye associated with infection or surgical intervention, and other abnormal neovascularization conditions of the eye; angiogenic aspects of skin diseases such as psoriasis; blood vessel diseases

30

such as hemangiomas, and capillary proliferation within atherosclerotic plaques; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and wound granulation. Other uses include the treatment of diseases characterized by excessive or abnormal stimulation of endothelial cells, including but not limited to intestinal adhesions, Crohn's disease, atherosclerosis, scleroderma, and hypertrophic scars, i.e. keloids. SSTR1 and SSTR4 selective agonists may also be useful in the treatment of diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochela ninalia quintosa*) and ulcers (*Helicobacter pylori*).

10

An alternative aspect of the invention comprises SSTR1 and SSTR4 selective agonist treatments for cancers susceptible to anti-angiogenic treatment, including both primary and metastatic solid tumors, including carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract, (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's sarcoma) and tumors of the brain, nerves, eyes, and meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, and meningiomas). In some aspects of the invention, SSTR1 and SSTR4 selective agonists may also be useful in treating solid tumors arising from hematopoietic malignancies such as leukemias (i.e. chloromas, plasmacytomas and the plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia) as well as in the treatment of lymphomas (both Hodgkin's and non-Hodgkin's lymphomas). In addition, SSTR1 and SSTR4 selective agonists may be useful in the prevention of metastases from the tumors described above either when used alone or in combination with radiotherapy and/or other chemotherapeutic agents.

In several aspects, the present invention relates to somatostatin receptor agonists that are selective for one or more of the somatostatin receptor subtypes. In this context, receptor-ligand binding assays may be carried out to determine the relative affinity of a compound for one or more of the somatostatin receptors, as for example is described by Rhorer *et al.*, 1998, *Science* 282:737. In some embodiments, a compound will be 'selective' for a receptor if the apparent inhibition constant of the compound with respect to that receptor ( $K_i$ , calculated as described by Rhorer *et al.*, *supra*) is less than the  $K_i$  of the compound with respect to another SS receptor, and in some embodiments at least ten fold less. In some embodiments, the selectivity of the agonists used in the invention may be greater than ten fold, such as 100 fold or 1000 fold. In some embodiments, the present invention encompasses compounds that are selective for more than one SSSTR.

In one aspect, the present invention utilises an established model system for studying human angiogenesis. The model system comprises the spontaneously transformed human umbilical vein endothelial cell line, ECV304, grown on a Matrigel substrate (Hughes, 1996, *Experimental Cell Research* 225:171-185). Matrigel is a solubilized basement membrane extract that promotes the differentiation of endothelial cells into capillary tube-like structures *in vitro*. It has been shown that cytoskeletal reorganization occurs when human umbilical vein endothelial cells undergo the morphological changes associated with neovascular tube formation on a Matrigel substrate (Grant *et al.*, 1991, *In Vitro Cell Dev. Biol.* 27A(4):327-36.). As disclosed in Example 1 herein, using the *in vitro* angiogenesis model comprising ECV304 cells on a Matrigel substrate, it has been shown in the context of the present invention that SS14 inhibits angiogenesis. At sub-micromolar and higher concentrations, SS14 was found to significantly inhibit neovascular growth in this model system. These results indicate that SS14, which is an agonist of all somatostatin receptor subtypes (see Table 1), acts on human endothelial cells as an angiogenesis inhibitor.

The present inventors have further demonstrated that the ECV304 cells only express the SSSTR1 and SSSTR4 receptor subtypes, and do not express SSSTR2, SSSTR3 or SSSTR5 mRNA in quantities detectable by RT-PCR (see Example 2). Accordingly,

the demonstrated anti-angiogenic effects of SS14 on ECV304 cells must be mediated by SSTR1 and/or SSTR4. The present inventors have also demonstrated that an SSTR1 selective agonist has similar physiological effects on ECV304 cells as does SS14, particularly disassembly of actin stress fibres and formation of lamellipodia (see Example 3). This indicates that in alternative embodiments of the invention, SSTR1 and SSTR4 selective agonists will have anti-angiogenic effects on human endothelial cells, just as SS14 has an anti-angiogenic effect in the ECV304/Matrigel model system.

Somatostatin analogues have been shown to have therapeutic effects in a variety of animal models of proliferative disease, including angiogenesis and intimal hyperplasia. SSTR2 agonists in particular have been shown to be successful in ameliorating the pathologies of endothelial-cell-mediated proliferative disease models, such as CAM, arterial balloon injury in several animal species, and murine angiogenesis in a cancer model. The present inventors have determined that in contrast to animal models in which endothelial cells express SSTR2 (see Example 4 and Chen *et al.*, 1997, *J. of Investigative Surgery* 10:17), human endothelial cells and tissues express SSTR1 and SSTR4. This indicates that, whereas SSTR2 agonists are effective in treating animal models of human endothelial-cell-mediated proliferative pathologies or disease, SSTR1 and SSTR4 selective agonists may be used to treat human patients.

Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. In the claims, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to". The following examples are illustrative of various aspects of the invention, and are not limiting of the broad aspects of the invention as disclosed herein.

**Example 1: Anti-Angiogenic Effect of SS14**

This example shows the anti-angiogenic effect of SS14 on endothelial cell capillary-like tube formation *in vitro*, using an established model of angiogenesis.

The model is based on the propensity of human endothelial cells, particularly

- 5 ECV304 cells, to form capillary-like tubes on Matrigel, a basement membrane extract (Hughes, 1996, *Experimental Cell Research* 225:171).

- Five mg vials of SS14 (Biomeasure Incorporated) were reconstituted using 1.0 mL 0.01% BSA/0.01N acetic acid/PBS to achieve a working stock of 3mM. The
- 10 human endothelial cell line ECV304 (ATCC) was cultured in Medium 199 (M199, Sigma) supplemented with 2 mM L-glutamine (Gibco BRL), 1 mM sodium pyruvate (Gibco BRL),  $5 \times 10^{-5}$  M 2-mercaptoethanol (Sigma), 100 U/mL penicillin (Gibco BRL), 100 µg/mL streptomycin (Gibco BRL), 20 mM HEPES (Sigma), and optionally 10% heat-inactivated fetal calf serum (Gibco BRL) or 1% BSA. Cells
- 15 were passed at a rate of 1:5 using 0.05% trypsin/0.005% EDTA (Gibco BRL) upon reaching confluence.

- ECV304 cells ( $3.5 \times 10^4$  in 0.5 mL complete M199 medium) were placed onto 24-well plates that were pre-coated with 0.125 mL of Matrigel (Becton-Dickinson).
- 20 SS14 was immediately added to the ECV304 cells and the cells were incubated at 37°C in a CO<sub>2</sub> humidified chamber. After 24 hours, images of tube-formation were recorded on film. Images were converted into a digital format using a Hewlett-Packard ScanJet 4C/T scanner, the summed length of capillary-like tubes was quantified using Optimas 6.1 image analysis software (Optimas Corp.).

- 25 Figure 2 illustrates in graphic form the finding that SS14 inhibits neovascular tube formation in a dose-dependent manner. The graph in Figure 2 shows that the inhibition of angiogenesis by SS14 was greater than 50% at all SS14 concentrations ranging from 0.1 µM to 100 µM, as measured by neovascular tube length relative to
- 30 control samples that were not treated with SS14.

**Example 2: Characterization of Human Endothelial Cells**

The endothelial characterization of the ECV304 cells used in the present invention was confirmed by the detection of von Willebrand Factor (vWF) mRNA by RT-PCR and the detection of vWF by immunocytochemistry (vWF is a well known functional marker of endothelial cells that is involved *in vivo* in the blood clotting cascade). The ECV304 cells used herein also expressed the endothelial marker endothelial nitric oxide synthase (eNOS).

RT-PCR provided evidence for the presence of SSTR1 and SSTR4 mRNA in ECV304 cells and in a primary endothelial HUVEC cell line from umbilical veins. Neither cell lines expressed SSTR2, SSTR3 or SSTR5 mRNA, with the exception that later passages of some HUVEC cultures showed low levels of SSTR2.

The ECV304 and HUVEC endothelial cell lines were immunostained for SSTR1 and vWF, identifying the location of the SS receptors. The ECV304 and HUVEC cell lines showed SSTR1 immunostaining in both the cytoplasm and on the plasma membrane. Localization of vWF in ECV304 cells and early passages of HUVEC cells showed that 95-100% of the cells were immunoreactive, however fewer cells were immunostained in the later passage of HUVECs (<60%).

In the present Example, ECV304 cells (American Type Culture Collection, Manassas, VA) were cultured in Medium 199 (Sigma Chemical Co., St. Louis, MO) supplemented with 2mM Glutamine, 24 mM sodium bicarbonate, 10 mM Hepes, penicillin (100 U/ml), streptomycin (0.1mg/ml), and heat inactivated fetal calf serum (10%). HUVEC and AoSMC cells were obtained from Clonetics Corporation (Walkersville, MD) with the required culture medium. The cell lines were grown in 75 cm<sup>2</sup> Falcon flasks (Becton Dickinson Labware, Franklin Lakes, NJ.) for collection of RNA or seeded onto APES (Sigma) coated 20mm coverslips in 24 well Costar plates (Corning Inc., Corning, NY) for histological studies. The following ECV304 cell line information is provided by the ATCC:

ATCC Number: CRL-1998, originally deposited in May 1992  
Organism: Homo sapiens (human)  
Designations: ECV304  
Tissue: normal; umbilical vein; endothelium; endothelial

Morphology: cobblestone

Depositors: K. Takahashi

VirusSuscept: Semliki Forest virus (SFV)

Tumorigenic: yes, in BALB/c nu/nu mice

5 Karyotype: modal number = 80

Products: angiotensin converting enzyme (ACE)

FluidRenewal: 2 to 3 times weekly

SubCulturing: Remove medium, add fresh 0.25% trypsin, 0.03% EDTA solution, rinse and remove trypsin. Allow the flask to sit at room temperature (or  
10 incubate at 37C) until the cells detach (usually 5 to 10 minutes). Add fresh medium, aspirate and dispense into new flasks.

SplitRatio: A ratio of 1:6 to 1:10 is recommended

Growth Properties: monolayer

Comments: ECV304 is a spontaneously transformed immortal endothelial cell  
15 line established from the vein of an apparently normal human umbilical cord (donor number 304). The cells are characterized by a cobblestone monolayer growth pattern, high proliferation potential without any specific growth factor requirement, and anchorage dependency with contact inhibition. Endothelium specific Weibel - Palade bodies were identified in electron microscopic studies. Immunocytochemical staining  
20 for lectin Ulex europaeus I (UEA-I) and PHM5 (anti-human endothelium as well as glomerular epithelium monoclonal antibody) was positive. The cells are negative for Factor VIII related antigen, for alkaline and acid phosphatases and for epithelial keratins. The cells will form tumors in BALB/c nu/nu mice, and will cause neovascularization on rabbit corneas. They are reported to produce pro-urokinase type  
25 PA (pro-u-PA) and express small amounts of intercellular adhesion molecule (ICAM-1), lymphocyte function associated antigen-3 (LFA-3). Vascular cell adhesion molecule (VCAM-1) and granular membrane protein-140 (GMP-140). Interleukin-1 (IL-1) and interferon exert suppressive effects on ECV304 cells. These cells also produce IL-6 after stimulation with IL-1. The line was cured of mycoplasma  
30 contamination by a 21 day treatment with BM Cycline. Further information may be included in the following references, which are hereby incorporated by reference: Takahashi *et al.*, 1990, *In Vitro Cell. Dev. Biol.* 26:265; Takahashi and Sawasaki, 1991, *In Vitro Cell. Dev. Biol.* 27A:766; Takahasi and Sawasaki, 1992, *In Vitro Cell.*

*Dev. Biol.* 28A:380). Propagation of the cell line may be carried out in ATCC Medium 199, 90%; heat-inactivated fetal bovine serum, 10%.

In the present Example, total RNA was isolated according to manufacturer's  
5 directions from tissue samples and cell lines lysed in Trizol solution (Gibco Life Technologies, Grand Island, N.Y.). Any DNA present was removed by incubation in the first strand buffer (25 mM Tris-HCl pH 8.3, 37.5 mM KCL, 1.5 mM MgCL<sub>2</sub> and 10 mM DTT) containing 1mM dNTPs (Pharmacia), 10 U Rnasin (Pharmacia), and 2U of Dnase (Promega Corporation, Madison, WI) and heated to 37°C for 30 min. The DNase was  
10 inactivated by heating to 75°C for 5 min. A sample was removed and used as a PCR template to verify the absence of genomic DNA. The cDNA was synthesized from purified RNA using Superscript II reverse transcriptase (100 U MMLV, Gibco Life Technologies, Grand Island, N.Y.) according to the manufacturer's directions with oligo-dT primer ((Gibco), 10 U Rnasin (Pharmacia), and 1 mM dNTPs (Pharmacia)). Samples  
15 were incubated at 42°C for 1 hour. The enzyme was inactivated by heating the samples to 75°C for 15 min. The cDNA samples were stored at -20°C prior to PCR.

For detection of SSTR subtypes in endothelial cell lines (and human blood vessels), oligonucleotide primers were synthesized on an Applied Biosystems Model  
20 391 DNA synthesizer, as follows:

TABLE 2: HUMAN SSTR PRIMERS

Primer specificity	Primer sequence (5'-3')	Position in gene	PCR product size	Annealing temperature
SSTR1	GGAGGAGCCGGTTGACTATT	1140-1159	375	58°C
	AAGGTAGCCTGAAAGCCTTCC	1494-1514		
SSTR2	AGAGCCGTACTATGACCTGA	184-203	627	59°C
	AGCCCACTCGGATTCCAGAG	793-812		
SSTR3	GAGCACCTGCCACATGCAGT	661-681	316	62°C
	CCCAAAGAAGGCAGGCTCCT	938-957		
SSTR4	TCCCTTATCCTCAGCTATGC	948-968	283	60°C
	CTCAGAAGGTGGTGGTCCTG	1211-1251		
SSTR5	TCTTCTCTTGCAGAGCCTGA	11-30	437	63°C
	TGACTGTCAGGCAGAAGACA	428-447		

SSTR-1, -2, -3, -4, and -5 primer pairs were designed to hybridize to unique regions of the receptors. The PCR reactions for SSTRs 1-5 were carried out using 2(l of

5 cDNA in 25 (l total volume of PCT buffer (67 mM Tris pH 9.01, 1.5 mM MgSO<sub>4</sub>, 166 mM AmSO<sub>4</sub>, and 10 mM (mercaptoethanol) containing 1mM MgCl<sub>2</sub> (5 mM MgCl<sub>2</sub> for SSTR5), 0.2 mM dNTPs (Pharmacia), 5% DMSO (SSTR5 only) and 100 ng of 5' and 3' primer. Taq polymerase (1.25 U, Gibco BRL). The amplification reaction was carried out in a RoboCycler Gradient 96 (Stratagene, La Jolla, CA) for 35 cycles. Each cycle

10 consisted of denaturation for 45 sec at 94°C, annealing for 45 sec at the relevant temperature (see Table 2), and an extension for 45 sec at 72°C. A final extension step at 72°C for 5 min terminated the amplification. The PCR products were separated by electrophoresis through a 1% agarose gel. The DNA was visualized and photographed using the Eagle Eye II Video System (Stratagene). The DNA fragments obtained using

15 primers for SSTR 1, 2 and 5 were isolated from the gels and ligated into pGEM-T (Stratagene, La Jolla, CA). DNA sequencing of the sub-clone was performed using the dideoxynucleotide chain-termination procedure with T7 sequenase (Pharmacia Biotech

Inc.). The DNA fragments obtained using primers for SSTR3, and 4 were eluted from the agarose gel and diagnostic restriction digest analysis performed to confirm that the PCR products were SSTR-3 and -4.

5 For detection of vWF in endothelial cells, oligonucleotide primers with the sequence: 5'CCCACCCTTTGATGAACACA3' for the forward primer and 5'CCTCACTTGCTGCACTTCCT3' for the reverse primer were used in PCR reactions to detect von Willebrand's factor (vWF) cDNA. The PCR reaction was performed in PCR buffer (20 mM Tris-HCl (pH8.4), 50 mM KCl) containing 2.0 mM MgCl<sub>2</sub>, 0.2  
10 mM dNTPs, (Pharmacia), 5% DMSO, and 100 ng of 5' and 3' primer with the addition of Taq polymerase (1.25 U, Gibco BRL). The 35 PCR cycles were performed as described above with an annealing temperature of 60°C. The PCR products were separated and visualized as above. The DNA fragment was isolated from the gel and diagnostic restriction digest analysis was performed to confirm the PCR product was  
15 VWF.

### Example 3: Effect of an SSTR1 Selective Agonist on Human Endothelial Cells

It has been demonstrated that SS acting through SSTR1 regulates intracellular pH (Barber *et al.*, 1989, *J. Biol. Chem.* 264:21038) and that intracellular pH in turn  
20 regulates actin stress fiber production (Tominaga *et al.*, 1998, *Mol. Biol. Cell.* 9:2287). The present Example illustrates the common effects of SS14 and an SSTR1 selective agonist on actin bundling in endothelial cells, using fluorescently labelled phalloidin to localise actin.

25 To assay the effect of SS14 on endothelial cells, ECV304 cells were washed to remove growth medium and fresh medium (lacking serum) added (1ml/well). The cells were cooled to 4°C for 15 minutes to concentrate SSTRs at the plasma membrane prior to the addition of SS14 (10nM, Peninsula Laboratories; Belmont, CA) to test wells while control wells received a similar volume of medium only. The cells were subsequently  
30 incubated at 37°C for 30 min, fixed in 4% PFA for 5 min and washed in PBS. The actin cytoskeleton was visualized by incubating the cells with ALEXA-488 conjugated phalloidin (1:50, Molecular Probes Inc., Eugene, OR) for 15 min at room temperature. Cells were screened using a Zeiss Axiophot microscope as previously described. Similar

protocols were used to evaluate the effects SSTR1 selective agonists on endothelial cells.

5 In control ECV304 cells abundant stress fibres stretching the entire length of the cell and few lamellipodia were observed. The SS14-treated ECV304 cells showed a loss of long stress fibers and the remaining fibers were short and lacked directional organization. In addition, there was an increase in the number and size of lamellipodia at the plasma membrane. In addition to these morphological changes, SS14 was shown to inhibit the Na/H exchanger on ECV304 cells, as determined by intracellular pH imaging. This indicates that monitoring changes to the actin cytoskeleton or intracellular pH are rapid and simple methods to follow activation of SS receptors on endothelial cells. In some embodiments, this assay may be used to screen for SSTR1 or SSTR4 selective agonists.

15 Treatment of ECV304 or HUVEC cells with the SSTR1 '499 agonist produced results similar to treatment of the cells with SS14. The result of SSTR1 '499 treatment was a decrease in stress fibres and an increase in lamellipodia formation. Treatment of ECV304 or HUVEC cells with a SSTR2 selective agonist, DC32-87 (Raynor *et al.*, 1993, *Mol. Pharmacol* 43(6):838) had no effect on the endothelial cells.

#### 20 Example 4: SSTRs in Human Endothelial Tissues v. Animal Tissues

In humans, the presence of mRNA for SSTR1, SSTR2 and SSTR4 (but not SSTR3 or SSTR5) was detected by RT-PCR in normal aorta, normal internal mammary artery, normal saphenous vein, and athlerosclerotic popliteal arteries. In all normal endothelial tissues, SSTR1 was expressed and was the most abundant of the receptor sub-types. The expression of SSTR2 and SSTR3 was more variable, with some individuals lacking expression of one of the two sub-types. In normal tissues, the abundance of the mRNA was lower for SSTR2 and SSTR3 compared to SSTR1.

Human artery samples (100-400 mg) were collected from bypass procedures, amputations or from human donors for organ transplantation in association with Pacific Organ Retrieval and Transplant Society with ethical permission from the Ethical Committee on Human Experimentation at the University of British Columbia. Normal veins N=6 (greater saphenous and arm), arteries N=5 (aorta and internal mammary) and diseased atherosclerotic or aneurysmal arteries N=3 were collected. The normal tissues used to obtain these results were as follows: 2 normal aortic samples, one from a 42-year-old woman and the second from a 19-year-old male; 3 internal mammary arteries and 3 saphenous veins from male patients ranging from 69-74 years of age. In athlerosclerotic popliteal arteries, SSTR1 was also the predominant receptor with variable levels of SSTR2 and SSTR4, again there was no evidence for the presence of SSTR3 or SSTR5. The 3 popliteal arteries were collected from male patients of 68, 72 and 73 years of age.

The vascular tissues analyzed herein include both endothelial and non-endothelial cells. In particular, non-endothelial smooth muscle cells form a substantial component of the vasculature. In a primary cell preparation of aortic smooth muscle cells, mRNAs for SSTR1, SSTR2 and SSTR4 were detected. In these aortic cell cultures, vWF mRNA was also detected, and vWF immunostaining (<10% of cells) was detected, indicating that the cultures included some endothelial cells.

Taken together with the results of the analysis of mRNA expression in human endothelial cells (Example 2), the results reported in this Example suggest that the SSTR2 mRNA detected in human vascular tissues originates with the non-endothelial cells in the tissues, while the SSTR1 and SSTR4 mRNA originates with the endothelial cells.

Immunocytochemistry was used to confirm that endothelial cells *in situ* expressed SSTR1. In normal and diseased blood vessels endothelial cells were immunostained by SSTR1 but not SSTR2 antibodies. Von Willebrand's Factor-immunoreactivity (IR) was limited to endothelial cells in normal and diseased vessels.

5 For immunocytochemistry, a small portion from each vessel sample was fixed in 4% paraformaldehyde ((PFA) for 1h and 10(m cryostat sections mounted on glass slides and cultured cells fixed for 10 min in PFA were used for immunocytochemistry. Rabbit antisera to human SSTR-1 (1:100) and SSTR-2 (1:100) (CURE/Gastroenteric Biology Center Antibody/RIA Core, NIH grant DK 41301) and VWF (Sigma; 1:1000) were

10 incubated on sections or whole cells at 4°C overnight. After washing in PBS to remove excess antibodies the bound antibodies were localized using Cy3 conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA.) at 1:1000 for 1h at room temperature. Slides were screened using a Zeiss Axiophot microscope equipped with epifluorescence. Representative sections were digitized using

15 a Biorad MRC 600 confocal laser scanning microscope equipped with a krypton argon laser. The resultant image stacks were converted to maximum intensity projections using NIH image (share ware) and the final images produced using Adobe Photoshop.

The results of assays of SSTRs in tissue from animal models may be

20 contrasted with the foregoing results from human tissues (see for a background example: Chen *et al.*, 1997, *J. Invest. Surg.* 10:17). In control samples of rodent iliac arteries no detectable immunoreactivity was observed to antisera specific for SSTR-1, 2 and 3. However, after injury, SSTR-2 immunoreactivity was observed on the surface of the endothelial cells re-populating the injured site. The identity of the

25 SSTR-2 immunoreactive cells and endothelial cells was confirmed by double staining with a monoclonal antibody to vWF. This immunocytochemical result indicates that SSTR-2 is the active SS receptor in the rat model of arterial injury. This was confirmed with RT-PCR using primers specific for the 5 known SSTRs. The results demonstrated that normal rat arteries expressed low levels of SSTR2 and SSTR3, but

30 not SSTR1, SSTR4 or SSTR5. A competitive PCR protocol was used to compare the levels of SSTR2 mRNA in control and injured vessels. The results using this protocol demonstrated a clear increase in expression levels of the SSTR2 receptor 7 days after balloon injury of the rat iliac arteries. Subsequent experiments demonstrated that this

increase was maintained for up to 2 months after injury. These animal model results are consistent with the ability of angiopeptin to inhibit intimal hyperplasia in rats, and hence the ability of SSTR1 and SSTR4 selective agonists to inhibit intimal hyperplasia in humans.

5

#### **Example 5: Therapeutic Formulations**

In one aspect, the invention provides a variety of therapeutic uses for SS agonists. In various embodiments, SSTR1 and SSTR4 selective agonists may be used therapeutically in formulations or medicaments for the treatment of human  
10 endothelial-cell-mediated proliferative diseases, such as pathological angiogenesis and intimal hyperplasia, including cancers susceptible to SSTR1 and SSTR4 selective agonists (such as susceptible solid tumors). The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a SS agonist is administered in a pharmacologically acceptable formulation. Accordingly, the  
15 invention also provides therapeutic compositions comprising a SS agonist and a pharmacologically acceptable excipient or carrier. The therapeutic composition may be soluble in an aqueous solution at a physiologically acceptable pH. In one aspect of the invention, SSTR1 and/or SSTR4 selective agonists may be administered using a perforated balloon catheter, as disclosed in International Patent Publication WO  
20 93/08866 of 13 May 1993, which is hereby incorporated by reference.

The invention provides pharmaceutical compositions (medicaments) containing (comprising) SS agonists. In one embodiment, such compositions include a SS agonist compound in a therapeutically or prophylactically effective amount  
25 sufficient to alter, and preferably inhibit, production of gamma interferon, and a pharmaceutically acceptable carrier. In another embodiment, the composition includes a SS agonist compound in a therapeutically or prophylactically effective amount sufficient to inhibit angiogenesis, and a pharmaceutically acceptable carrier.

30 The SSTR1 and SSTR4 selective agonists may be used in combination with other compositions and procedures for the treatment of diseases. For example, a tumor may be treated conventionally with photodynamic therapy, surgery, radiation or chemotherapy combined with a SSTR1 or SSTR4 selective agonist, and then a SSTR1

or SSTR4 selective agonist may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residual primary tumor.

5           A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduction or reversal of angiogenesis in the case of cancers, or reduction or inhibition of intimal hyperplasia. A therapeutically effective amount of SS agonist may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the SS agonist to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the SS agonist are outweighed by the therapeutically beneficial effects.

15           A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as preventing or inhibiting the rate of metastasis of a tumour or the onset of intimal hyperplasia. A prophylactically effective amount can be determined as described above for the therapeutically effective amount. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

25           In particular embodiments, a preferred range for therapeutically or prophylactically effective amounts of a SSTR1 or SSTR4 selective agonist may be 0.1 nM-0.1M, 0.1 nM-0.05M, 0.05 nM-15µM or 0.01 nM-10µM. Alternatively, total daily dose may range from about 0.001 to about 1mg/kg of patients body mass. Dosage values may vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the methods of the invention.

The amount of active SSSTR selective agonist in a therapeutic composition may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

As used herein "pharmaceutically acceptable carrier" or "excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Alternatively, the carrier can be suitable for intravenous, intraperitoneal, intramuscular, sublingual or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a

solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity  
5 can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought  
10 about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the SS agonists can be administered in a time release formulation, for example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including  
15 implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.

20

Sterile injectable solutions can be prepared by incorporating the active compound (e.g. SS agonist) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active  
25 compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered  
30 solution thereof. In accordance with an alternative aspect of the invention, a SS agonist may be formulated with one or more additional compounds that enhance the solubility of the SS agonist.

A further form of administration is to the eye. An SSTR1 or SSTR4 selective agonist may be delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, as for example the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera. The pharmaceutically-acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating material. Alternatively, the compounds of the invention may be injected directly into the vitreous and aqueous humour. In a further alternative, the compounds may be administered systemically, such as by intravenous infusion or injection, for treatment of the eye. In some embodiments, anti-angiogenic treatment with SSTR1 or SSTR4 agonists may be undertaken following photodynamic therapy (such as is described in U.S. 5,798,349 issued 25 August 1998, incorporated herein by reference).

15

In accordance with another aspect of the invention, therepeutic compositions of the present invention, comprising SSTR1 or SSTR4 selective agonists, may be provided in containers having labels that provide instructions for use of SSTR1 or SSTR4 selective agonists to treat endothelial-cell-mediated proliferative diseases.

20

## WHAT IS CLAIMED IS:


1. The use of a SSTR1 or SSTR4 selective agonist to formulate a medicament for use to treat an endothelial-cell-mediated proliferative disease.
- 5 2. The use of a SSTR1 or SSTR4 selective agonist for treating an endothelial-cell-mediated proliferative disease in a human patient.
3. The use of the SSTR1 or SSTR4 selective agonist according to claim 1 or 2, wherein the endothelial-cell-mediated proliferative disease is intimal  
10 hyperplasia.
4. The use of the SSTR1 or SSTR4 selective agonist according to claim 1 or 2, wherein the endothelial-cell-mediated proliferative disease is an angiogenic disease.
- 15 5. The use of the SSTR1 or SSTR4 selective agonist according to claim 4, wherein the angiogenic disease is age-related macular degeneration.
6. The use of the SSTR1 or SSTR4 selective agonist according to claim 4,  
20 wherein the angiogenic disease is a solid tumor.
7. The use of the SSTR1 or SSTR4 selective agonist according to any one of claims 1 through 6, wherein the SSTR1 or SSTR4 selective agonist is des-AA<sup>1,2,5</sup> [DTrp<sup>8</sup>, JAamp<sup>9</sup>]SS.
- 25 8. The use of the SSTR1 or SSTR4 selective agonist according to any one of claims 1 through 6, wherein the SSTR1 or SSTR4 selective agonist is an SSTR1 selective agonist.
- 30 9. The use of the SSTR1 or SSTR4 selective agonist according to any one of claims 1 through 7, wherein the SSTR1 or SSTR4 selective agonist is an SSTR4 selective agonist.

10. A method for treating an endothelial-cell-mediated proliferative disease comprising administering to a human patient in need thereof a therapeutically effective amount of a SSTR1 or SSTR4 selective agonist.
- 5 11. The method according to claim 10, wherein the endothelial-cell-mediated proliferative disease is intimal hyperplasia.
12. The method according to claim 10, wherein the endothelial-cell-mediated proliferative disease is an angiogenic disease.
- 10 13. The method according to claim 12, wherein the angiogenic disease is age-related macular degeneration.
14. The method according to claim 12, wherein the angiogenic disease is a solid tumor.
- 15 15. The method according to any one of claims 10 through 14, wherein the SSTR1 or SSTR4 selective agonist is des-AA<sup>1,2,5</sup> [DTrp<sup>8</sup>,IAamp<sup>9</sup>]SS.
- 20 16. The method according to any one of claims 10 through 14, wherein the SSTR1 or SSTR4 selective agonist is a SSTR1 selective agonist.
17. The method according to any one of claims 10 through 14, wherein the SSTR1 or SSTR4 selective agonist is a SSTR4 selective agonist
- 25 18. A method for inhibiting angiogenesis, comprising administering to a human patient in need thereof an effective amount of a SSTR1 or SSTR4 selective agonist.
- 30 19. A method for inhibiting intimal hyperplasia, comprising administering to a human patient in need thereof an effective amount of a SSTR1 or SSTR4 selective agonist.

20. A composition for the treatment of an endothelial-cell-mediated proliferative disease comprising a SSTR1 or SSTR4 selective agonist in combination with a pharmaceutically acceptable carrier.
- 5 21. A method for modulating the activity of human endothelial cells, comprising treating the cells with an effective amount of a SSTR1 or SSTR4 selective agonist.
22. The method of claim 21, wherein the activity of the human endothelial cells is modulated to inhibit angiogenesis.
- 10 23. The method of claim 21 wherein the activity of the human endothelial cells is modulated to have an effect on the cells, wherein the effect is the same as the effect somatostatin would have.

15

Figure 1



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 99/00800

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/31 A61P5/02 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	REUBI, J-C ET AL: "A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors" EUR. J. PHARMACOL., vol. 345, no. 1, 12 March 1998 (1998-03-12), pages 103-110, XP000876543 page 109, last sentence	1,2,4, 6-8,10, 12, 14-16, 20-23
X	WO 97 43278 A (NOVONORDISK AS ;ANDERSEN HENRIK SUNE (DK); ANKERSEN MICHAEL (DK);) 20 November 1997 (1997-11-20) claim 30	20,21,23
	---	
	--- --	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

10 February 2000

Date of mailing of the international search report

01/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Teyssier, B

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00800

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 98 58646 A (NOVONORDISK AS) 30 December 1998 (1998-12-30)</p> <p>page 2, line 21; claims</p>	<p>1,2,4,5, 8-10,12, 13,16, 17,20, 21,23</p>
E	<p>WO 99 49884 A (PATEL YOGESH C ;HAEYRY PEKKA (FI); JUVANTIA PHARMA LTD OY (FI)) 7 October 1999 (1999-10-07) page 5, line 8 -page 6, line 16 claims 1-9</p>	<p>1-4, 7-12, 15-23</p>
A	<p>HIRSCHMANN R ET AL: "Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis." JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 9, 4 April 1998 (1998-04-04), pages 1382-1391, XP002130093 figure 10</p>	<p>1-23</p>
A	<p>WO 97 03054 A (SANDOZ LTD ;SANDOZ AG (DE); SANDOZ AG (AT); NEUMANN PETER (CH); PF) 30 January 1997 (1997-01-30) claims</p>	<p>1-23</p>

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/00800

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 10-19 and 21-23 are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00800

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9743278 A	20-11-1997	AU 2764797 A EP 0912551 A	05-12-1997 06-05-1999
WO 9858646 A	30-12-1998	AU 7907198 A	04-01-1999
WO 9949884 A	07-10-1999	NONE	
WO 9703054 A	30-01-1997	AU 703325 B AU 6612096 A BR 9609326 A CA 2224436 A CN 1193964 A CZ 9800016 A EP 0839136 A HU 9802937 A JP 11509197 T NO 980043 A NZ 313606 A PL 324106 A SK 1798 A US 5885988 A	25-03-1999 10-02-1997 25-05-1999 30-01-1997 23-09-1998 15-04-1998 06-05-1998 28-10-1999 17-08-1999 05-01-1998 29-07-1999 11-05-1998 03-06-1998 23-03-1999